Story at-a-glance
- The FDA has authorized the use of a booster COVID-19 shot in children ages 5 to 11; less than one-third — only 28.8% — of U.S. children in this age group have received the first two doses of this experimental gene therapy
- Effectiveness of COVID-19 shots in children wanes rapidly; a CDC study found that two to four weeks after the second dose of Pfizer’s COVID-19 shots, effectiveness was 60.1% among 5- to 11-year-olds, but this fell to just 28.9% by month two
- There is still no data on whether the booster is effective against COVID-19, and whether the effectiveness will quickly wane, as it has with all previous shots as well as booster doses in adults
- Artificially inflated antibodies triggered by booster shots signal to your body that you’re always infected, and the resulting immune response could prove to be detrimental to your health
- COVID-19 shots are associated with liver injury, including liver failure that led to a liver transplant
- Children are at an extremely low risk of serious illness from COVID-19, and CDC data show that COVID-19 case rates among children who received two COVID-19 shots are now higher than rates in children who did not get the shots
The U.S. Food and Drug Administration amended its emergency use authorization for the Pfizer-BioNTech COVID-19 shot to allow a booster dose for children ages 5 to 11.1 The FDA’s “evaluation of safety” for the booster dose in young children was based on a study of only about 400 children, and no meeting was held with the Vaccines and Related Biological Products Advisory Committee.
Continue reading “107 Times the Risk, Are ‘Boosters’ Designed to Kill?”
